New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
10:29 EDTABBV, SNY, JNJJohnson & Johnson advances after Jefferies upgrade
Shares of Johnson & Johnson (JNJ) are climbing after Jefferies upgraded its rating on the stock. WHAT'S NEW: Johnson & Johnson's stock has reached "a great entry point," Jefferies analyst Jeffrey Holford wrote in a note to investors. The execution of the company's pharmaceutical business continues to be excellent, Holford believes. The unit's growth is being driven by the company's Zytiga prostate cancer treatment and its Xarelto drug which is used to reduce the risk of stroke and blood clots in people with atrial fibrillation, as well as another drug, Invokana, which improves glycemic control in some diabetes patients, the analyst contended. In the future Johnson & Johnson will also be helped by some of its new products, and investors are under-appreciating this upcoming catalyst, added Holford. Meanwhile, the company's consumer business should rebound, as its manufacturing issues should no longer have much of an impact on revenue, the analyst stated. The analyst is also more upbeat on the company's ibrutnib treatment for mantle cell lymphoma He upgraded the stock to Buy from Hold and raised his price target on the shares to $108 from $102. WHAT'S NOTABLE: Sanofi (SNY) is Holford's top European pick in the pharmaceutical market, while AbbVie (ABBV) is his top American pick. PRICE ACTION: In mid-morning trading, Johnson & Johnson rose 70c, or 0.74%, to $94.84.
News For JNJ;SNY;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
16:17 EDTSNYArdelyx regains NaP2b program from Sanofi
Subscribe for More Information
09:01 EDTSNYRegeneron and Sanofi announces Praluent Phase 3 data
Regeneron (REGN) and Sanofi (SNY) announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia patients included in the ODYSSEY clinical trial program, Praluent significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol. This analysis included 1,257 HeFH patients, the largest group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with Praluent had an average 56 percent greater reduction in LDL-C compared to placebo in both arms. Reductions were observed as early as week 4 and were maintained for the duration of therapy, until week 78.
07:31 EDTABBVBristol-Myers, AbbVie say FDA accepts BLA for Empliciti for priority review
Subscribe for More Information
August 31, 2015
14:00 EDTABBVAbbVie September calls active
AbbVie September 65 and 67.5 calls are active on total call volume of 37K contracts (9K puts). September weekly call option implied volatility is at 37, September is at 36, October is at 31; compared to its 52-week range of 18 to 36. Active call volume suggests traders taking positions for price movement.
09:07 EDTSNYSanofi, Google Life Sciences to collaborate to improve diabetes health outcomes
Subscribe for More Information
06:35 EDTSNYAlnylam price target raised to $184 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $184 saying the company over the weekend reported positive Phase I data on ALN-PCS showing LDL-cholesterol lowering comparable to Amgen (AMGN) and Sanofi/Regeneron's (REGN) anti-PCSK9 antibodies, but with only quarterly or potentially every 6-month injections. Tenthoff recommends using the recent pullback in shares of Alnylam as a buying opportunity and keeps an Overweight rating on the name.
August 30, 2015
15:50 EDTSNYAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
08:01 EDTSNYAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:49 EDTJNJJohnson & Johnson to open shared services headquarters in Florida
Subscribe for More Information
19:14 EDTSNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
August 25, 2015
19:34 EDTABBVExperts tell White House to expand use of Hepatitis C drugs, NYT says
Health care experts from the Public Health Service and the Advisory Council on H.I.V./AIDS have recommended that Medicaid officials expand the use of costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni, reports the New York Times, citing correspondence sent to the White House. The advisory council said current usage limitations on the drugs are "unreasonable," but it also suggested that manufacturers disclose drug development costs in the face of the significant price tags on modern Hepatitis C treatments. Reference Link
13:01 EDTJNJJ&J unit to sell Splenda brand to Heartland Food, terms not disclosed
Subscribe for More Information
09:03 EDTJNJ, ABBVAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
06:18 EDTJNJSears names Lynn Pendergrass as Hardlines president
Subscribe for More Information
August 21, 2015
09:01 EDTJNJLeerink medical devices analyst holds an analyst/industry conference call
Medical Device Analyst Newitter, along with MEDACorp Specialists Dorance Dillon and Terence Farrell, discuss the Centers for Medicare & Medicaid Services' recently proposed "Comprehensive Care For Joint Replacement Payment Model" and how this model might influence ortho pricing and hospital-vendor relationships on an Analyst/Industry conference call to be held on August 24 at 1 pm.
August 20, 2015
11:33 EDTSNY, JNJLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
August 19, 2015
06:09 EDTABBVUnited Therapeutics agrees to sell PPRV to AbbVie for $350M
United Therapeutics (UTHR) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher, or PPRV, to a subsidiary of AbbVie (ABBV). United Therapeutics received the PPRV when Unituxin was approved by the FDA for the treatment of neuroblastoma, a rare pediatric disease. Upon closing of the transaction, United Therapeutics will receive $350M in cash in exchange for the PPRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.
05:57 EDTABBVAbbVie implied volatility of 20 at lower end of index mean range

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use